Characteristics of patients with paradoxical articular manifestation
| n=23 | |
| Female gender, n (%) | 14 (60.8) |
| Male gender, n (%) | 9 (39.2) |
| Age | |
| Mean (SD) | 32.2 (10.6) |
| Median (Q1 ; Q3) | 30.0 (24.5 ; 39.0) |
| IBD type | |
| Crohn disease, n (%) | 14 (60.9) |
| Ulcerative colitis, n (%) | 9 (39.1) |
| Disease duration (years) | |
| Mean (SD) | 5.3 (0.8) |
| Median (Q1 ; Q3) | 0 (0 ; 5.5) |
| Previous articular manifestations, n (%) | 6 (26,1) |
| Spondyloarthritis, n (%) | 5 (21.7) |
| Arthralgia concomitant of IBD’s flare, n (%) | 1 (4.3) |
| Anti-TNFa at the time of paradoxical articular manifestation: | |
| Infliximab, n (%) | 18 (78.3) |
| Adalimumab, n (%) | 5 (21.7) |
| Associated immunosuppressive treatment | 8 (34.7) |
| Methotrexate, n (%) | 1 (4.3) |
| Azathioprine, n (%) | 5 (21.7) |
| Purinethol, n (%) | 2 (8.7) |
| Anti-TNFa’s line: | |
| First, n (%) | 19 (82.7) |
| Second, n (%) | 3 (13) |
| Third, n (%) | 1 (4.3) |
| Time between anti-TNFa’s initiation and occurrence of articular manifestation: | |
| Mean (SD) | 29.4 (13.4) |
| Median (Q1; Q3) | 24.0 (10.5; 34.0) |
| Paradoxical articular manifestation’s characteristics: | |
| Peripheral, n (%) | 18 (78.2) |
| Arthralgia, n (%) | 13 (56.4) |
| Arthritis, n (%) | 5 (21.8) |
| Enthesitis, n (%) | 1 (4.3) |
| Axial, n (%) | 2 (8.7) |
| Peripheral and/or enthesitis and axial, n (%) | 2 (8.7) |
| HLA B 27: | |
| Negative, n (%) | 1 (4.3) |
| Unknown, n (%) | 22 (95.7) |
| CRP: | |
| Unknown, n (%) | 1 (4.3) |
| Mean, mg/L (SD) | 11.9 (18.7) |
| Median, mg/L (Q1 ; Q3) | 7.0 (1.0 ; 24.0) |
| Anti-TNFa Abs: | |
| Negative, n (%) | 21 (91.3) |
| Unknown, n (%) | 2 (8.7) |
| Anti-TNFa dosage | |
| Mean, mg/mL (SD) | 9.5 (7.3) |
| Median, mg/mL (Q1 ;Q3) | 9.5 (8.8 ;10.2) |
| Unknown, n (%) | 2 (8.7) |
| Management: | |
| Continuation anti-TNFa, n (%) | 17 (74) |
| Addition of another immunosuppressive therapy, n (%) | 2 (8.7) |
| Discontinuation of anti-TNFa, n (%) | 4 (17.3) |
| Switch for another anti-TNFa, n (%) | 3 (13.0) |
| Continuation of immunosuppressive therapy alone, n (%) | 1 (4.3) |
CRP, C reactive protein; IBD, inflammatory bowel disease; TNF, tumour necrosis factor.